Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells

Oncogene

Volumn 34, Issue 17, 2015, Pages 2251-2260

  Kobayashi, T ^a   Masoumi, K C ^a   Massoumi, R ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYLD PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RETINOIC ACID; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR SUPPRESSOR PROTEIN;

BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; NEUROBLASTOMA; PATHOLOGY; SIGNAL TRANSDUCTION; SUMOYLATION; TUMOR CELL LINE; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEUROBLASTOMA; NF-KAPPA B; SIGNAL TRANSDUCTION; SUMOYLATION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRETINOIN; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84933525942     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.159     Document Type: Article

References (43)

1. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 2009; 107: 46-57.
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
4. Anderson DJ, Axel R. A bipotential neuroendocrine precursor whose choice of cell fate is determined by NGF and glucocorticoids. Cell 1986; 47: 1079-1090.
5. Anderson DJ, Carnahan JF, Michelsohn A, Patterson PH. Antibody markers identify a common progenitor to sympathetic neurons and chromaffi n cells in vivo and reveal the timing of commitment to neuronal differentiation in the sympathoadrenal lineage. J Neurosci 1991; 11: 3507-3519.
6. Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 2008; 105: 14094-14099.
7. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993; 53: 2044-2050.
8. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120.
9. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165-1173.
10. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group Study. J Clin Oncol 2009; 27: 1007-1013.
11. Sidell N, Altman A, Haussler MR, Seeger RC. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 1983; 148: 21-30.
12. Pahlman S, Ruusala AI, Abrahamsson L, Mattsson ME, Esscher T. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ 1984; 14: 135-144.
13. Ortoft E, Pahlman S, Andersson G, Parrow V, Betsholtz C, Hammerling U. Human GAP-43 gene expression: multiple start sites for initiation of transcription in differentiating human neuroblastoma cells. Mol Cell Neurosci 1993; 4: 549-561.
14. Kaplan DR, Matsumoto K, Lucarelli E, Thiele CJ. Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group. Neuron 1993; 11: 321-331.
15. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985; 313: 404-406.
16. Clagett-Dame M, McNeill EM, Muley PD. Role of all-trans retinoic acid in neurite outgrowth and axonal elongation. J Neurobiol 2006; 66: 739-756.
17. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000; 25: 160-165.
18. Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer. Fut Oncol 2011; 7: 285-297.
19. Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A, et al. The structure of the CYLD USP domain explains its specifi city for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 2008; 29: 451-464.
20. Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009; 10: 466-473.
21. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 2003; 424: 793-796.
22. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-677.
23. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-[kappa]B signalling by deubiquitination. Nature 2003; 424: 801-805.
24. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797-801.
25. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483: 589-593.
26. Kohl NE, Gee CE, Alt FW. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 1984; 226: 1335-1337.
27. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116.
28. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol 2011; 21: 256-266.
29. Feng Z, Porter AG. NF-κB/Rel proteins are required for neuronal differentiation of SH-SY5Y neuroblastoma cells. J Biol Chem 1999; 274: 30341-30344.
30. Kiningham KK, Cardozo Z-A, Cook C, Cole MP, Stewart JC, Tassone M, et al. All-trans-retinoic acid induces manganese superoxide dismutase in human neuroblastoma through NF-κB. Free Radic Biol Med 2008; 44: 1610-1616.
31. Bryan B, Kumar V, Stafford LJ, Cai Y, Wu G, GEFT Liu M, et al. Family guanine nucleotide exchange factor, regulates neurite outgrowth and dendritic spine formation. J Biol Chem 2004; 27945824-45832.
32. Liu T-X, Zhang J-W, Tao J, Zhang R-B, Zhang Q-H, Zhao C-J, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000; 96: 1496-1504.
33. Deyrieux AF, Rosas-Acosta G, Ozbun MA, Wilson VG. Sumoylation dynamics during keratinocyte differentiation. J Cell Sci 2007; 120: 125-136.
34. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature Rev Cancer 2013; 13: 397-411.
35. Bauters TG, Laureys G, Van de Velde V, Benoit Y, Robays H. Practical implications for the administration of 13-cis retinoic acid in pediatric oncology. Int J Clin Pharm 2011; 33: 597-598.
36. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-361.
37. Chen J, Chen ZJ. Regulation of NF-κB by ubiquitination. Curr Opin Immunol 2013; 25: 4-12.
38. Lovat PE, Irving H, Annicchiarico-Petruzzelli M, Bernassola F, Malcolm AJ, Pearson AD, et al. Apoptosis of N-type neuroblastoma cells after differentiation with 9-cis-retinoic acid and subsequent washout. J Natl Cancer Inst 1997; 89: 446-452.
39. Celay J, Blanco I, Lazcoz P, Rotinen M, Castresana JS, Encio I. Changes in gene expression profiling of apoptotic genes in neuroblastoma cell lines upon retinoic acid treatment. PLoS ONE 2013; 8: e62771.
40. O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol 2011; 13: 1437-1442.
41. Wright A, Reiley WW, Chang M, Jin W, Lee AJ, Zhang M, et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 2007; 13: 705-716.
42. Lee Moon H, Mabb Angela M, Gill Grace B, Yeh Edward TH, Miyamoto S. NF-κB Induction of the SUMO protease SENP2: a negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell 2011; 43: 180-191.
43. Wilkinson KA, Nakamura Y, Henley JM. Targets and consequences of protein SUMOylation in neurons. Brain Res Rev 2010; 64: 195-212.